Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Hakodate Goryoukaku Hospital

2 abstracts

Abstract
Cost-effectiveness study of atezolizumab (ATZ) vs. durvalumab (DUR): Real-world data (RWD) on first-line chemotherapy combined with immune-checkpoint inhibitors (Chemo-ICIs) for extensive disease small-cell lung cancer (ED-SCLC).
Org: Kobe Minimally Invasive Cancer Center, Hakodate Goryoukaku Hospital, Fujita Health University Hospital, Onomichi General Hospital, Takarazuka City Hospital,
Abstract
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).
Org: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tohoku University Graduate School of Medicine, Nippon Medical School Hospital, Niigata University Graduate School of Medical and Dental Sciences, Japanese Red Cross Okayama Hospital,